San Diego, CA -- (SBWIRE) -- 06/24/2013 -- An investigation on behalf of investors of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) shares over potential securities laws violations by Vanda Pharmaceuticals Inc. and certain of its directors and officers in connection certain financial statements was announced.

Investors who purchased shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) have certain options and should contact the Shareholders Foundation at mail(at)shareholdersfoundation.com or call +1(858) 779 - 1554.

The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) concerning whether a series of statements by Vanda Pharmaceuticals regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

Vanda Pharmaceuticals Inc. reported that its annual Total Revenue rose from $31.27 million in 2011 to $32.73 million in 2012 and that its respective Net Loss increased from $9.80 million to $27.66 million.

Shares of
Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) grew from $3.80 in early 2013 to as high as $13.25 per share on June 12, 2013.

Then on June 13, 2013, an article was published that alleged that the design of Vanda Pharmaceuticals’ primary phase III study changed numerous times, including a complete replacement of the primary endpoint just one month before study results were announced.

The article also alleged that during the tasimelteon clinical trials, Vanda Pharmaceuticals cut half the patient enrollment because the blind patients with non-24 could not be identified.

Shares of Vanda Pharmaceuticals Inc. declined from over $13 per share on June 12, 2013 to as low as $8.47 per share on June 19, 2013.

On June 21, 2013, NASDAQ:VNDA shares closed at $8.27 per share.

Those who purchased shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA), have certain options and should contact the Shareholders Foundation.

Contact:
Shareholders Foundation, Inc.
Trevor Allen
3111 Camino Del Rio North - Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com